The results of the European Trial On Reduction of Cardiac Events With Perindopril in Stable Coronary Artery Disease (EUROPA), first presented at last year's European Society of Cardiology (ESC) ...

Perindopril is a long-acting ACE inhibitor, prescribed for high blood pressure, heart attack and heart failure. We recommend consulting your doctor to verify the information presented on this page or ...

The Perindopril in Elderly People with Chronic Heart Failure study failed to show that perindopril could reduce long-term mortality or morbidity among elderly people with diastolic with heart failure.

Learn everything you need to know about Perindopril-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings ...

A fixed combination of perindopril (an ACE inhibitor) plus indapamide (a diuretic), available under the brand name Preterax, was evaluated in a randomized trial (Lancet. 2007;370:829-840). Patients ...

PICXEL was designed to evaluate the effects of long-term administration of a very low-dose combination of perindopril plus indapamide (perindopril/indapamide) vs ...

The aim of our study was to compare glucose homeostasis, serum lipid profile, fibrinolytic activity, albumin excretion rate (AER), and homocysteine (Hct) in patients with mild hypertension and type II ...

Continuing a trend in secondary prevention, the FDA has approved perindopril for the treatment of patients with stable coronary artery disease to reduce the risk of cardiovascular mortality and ...

What to do: If your bottle of ezetimibe 10 mg tablets contains any perindopril 4 mg tablets, or if you are unsure, return it to your pharmacy immediately. If you are unable to return your tablets to ...

The "high tissue" ACE inhibitor, perindopril significantly reduces the risk of death, hospitalisation for HF and cardiac remodeling in elderly post MI patients with preserved LV function according to ...

Whereas in the past, most hypertension guidelines focussed primarily on which drug was the best single agent, physicians are now encouraged to add a second (or third) drug rather than having ...

BERKELEY, Calif., July 3, 2013 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today it has transferred U.S.